Search

Your search keyword '"Jimeno, Antonio"' showing total 1,089 results

Search Constraints

Start Over You searched for: Author "Jimeno, Antonio" Remove constraint Author: "Jimeno, Antonio"
1,089 results on '"Jimeno, Antonio"'

Search Results

2. The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.

3. Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.

4. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

5. Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer

6. Efficacy of different 8 h time-restricted eating schedules on visceral adipose tissue and cardiometabolic health: A study protocol

7. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

8. Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft

9. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.

10. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma

12. Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells

13. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.

14. Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma

15. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

18. Leading edge or tumor core: Intratumor cancer stem cell niches in oral cavity squamous cell carcinoma and their association with stem cell function.

19. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.

20. Inter‐ and intra‐tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas

21. Wnt signaling dynamics in head and neck squamous cell cancer tumor‐stroma interactions

23. Whole‐body volume of oxygen consumption while walking: Agreement between measured and estimated values.

25. Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.

26. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.

27. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

30. Impact of lifestyle moderate‐to‐vigorous physical activity timing on glycemic control in sedentary adults with overweight/obesity and metabolic impairments

31. Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center.

32. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

33. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer

34. Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.

35. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.

36. Cancer Stem Cells in Squamous Cell Carcinoma.

37. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

38. Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.

39. Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

40. Time-restricted eating and supervised exercise for improving hepatic steatosis and cardiometabolic health in adults with obesity: protocol for the TEMPUS randomised controlled trial

41. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.

42. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

43. Head and Neck Cancers, Version 1.2015.

45. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

46. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

47. Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.

48. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

49. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

50. 594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+tumors treated with cell-based vaccine, SQZ-PBMC-HPV

Catalog

Books, media, physical & digital resources